Supplementary Online Content 2. Kaye KS, Bhowmick T, Metallidis S, et al. Effect of meropenem-vaborbactam vs piperacillin-tazobactam on
|
|
|
- Allan Black
- 5 years ago
- Views:
Transcription
1 Supplementary Online Content 2 Kaye KS, Bhowmick T, Metallidis S, et al. Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection. JAMA. doi: /jama efigure 1. Study Schema etable 1. Distribution of Patients by Site etable 2. Baseline Characteristics etable 3. Drug Resistance by EUCAST Criteria in Baseline Urinary Gram-Negative Pathogens (m-mitt population) etable 4. Overview of Adverse Events (MITT Population) ereferences This supplementary material has been provided by the authors to give readers additional information about their work.
2 efigure 1. Study Schema
3 etable 1. Distribution of Patients by Site Country Site/ID No. Patients Belarus Belarus Belarus Belarus Belarus Belarus Brazil Brazil Brazil Brazil Bulgaria Bulgaria Bulgaria Bulgaria Bulgaria Bulgaria Czech Republic Czech Republic Czech Republic Czech Republic Czech Republic Greece Greece Greece Greece Hungary Italy Peru Peru Peru Peru Poland Poland Poland Romania
4 Country Site/ID No. Patients Romania Romania Slovakia Slovakia Slovakia Slovenia Slovenia South Korea Spain Spain Taiwan Taiwan Ukraine Ukraine Ukraine Ukraine Ukraine Ukraine Ukraine Ukraine United States United States United States United States United States TOTAL 550
5 etable 2. Baseline Characteristics Baseline characteristics m-mitt population M-V (N=192) P-T (N=182) M-V (N=178) ME population P-T (N=169) Acute pyelonephritis, n (%) 120 (62.5) 101 (55.5) 111 (62.4) 92 (54.4) Complicated UTI, n (%) With removable source of infection a With nonremovable source of infection 72 (37.5) 35 (18.2) 37 (19.3) 81 (44.5) 38 (20.9) 43 (23.6) 67 (37.6) 34 (19.1) 33 (18.5) 77 (45.6) 34 (20.1) 43 (25.4) Age (y): mean (SD) 65 y, n (%) 53.1 (19.3) 62 (32.3) 55.5 (20.5) 77 (42.3) 53.2 (19.3) 55 (30.9) 54.5 (20.3) 68 (40.2) Gender, female, n (%) 125 (65.1) 120 (65.9) 115 (64.6) 112 (66.3) Race, white, n (%) 178 (92.7) 169 (92.9) 166 (93.3) 158 (93.5) Creatinine clearance (ml/min): mean (SD) 50 ml/min, n (%) 95.0 (34.7) 21 (10.9) 87.0 (35.5) 23 (12.6) 176 (35.4) 20 (11.2) 166 (35.1) 20 (11.8) Diabetes mellitus, n (%) 32 (16.7) 34 (18.7) 29 (16.3) 30 (17.8) Systemic inflammatory response syndrome b, n (%) 55 (28.6) 61 (33.5) 52 (29.2) 57 (33.7) Charlson Comorbidity Index c Score 3, n (%) 103 (53.6) 105 (57.7) 95 (53.4) 94 (55.6) Abbreviations: ME, microbiologic evaluable; m-mitt, microbiologic modified intent-to-treat; M-V, meropenem-vaborbactam; P-T, piperacillin-tazobactam; SD, standard deviation. a Removable source of infection includes urinary catheter or removable kidney stones. b Systemic inflammatory response syndrome is defined as the occurrence of 2 or more of the following: Fever of >38 C (100.4 F) or <36 C (96.8 F); heart rate of >90 beats per minute; respiratory rate of >20 breaths per minute or arterial carbon dioxide tension of <32 mm Hg; abnormal white blood cell count (>12,000/µL or <4,000/µL or >10% immature [band] forms) c Charlson Comorbidity Index is used to categorize comorbidities of patients based on the International Classification of Diseases diagnosis codes. Each comorbidity category has an associated weight ranging from 1 to 6, based on the adjusted risk of mortality or resource use. The sum of all the weights results in a comorbidity score. A higher score indicates a higher likelihood that the predicted outcome will result in mortality or higher resource use.
6 etable 3. Drug Resistance by EUCAST Criteria in the Most Common Baseline Urinary Gram- Negative Pathogens (m-mitt Population) No. (%) Resistant: EUCAST Criteria a,1,2 Drug resistance Antimicrobial M-V n (%) b P-T n (%) b Escherichia coli N =124 N =115 Meropenem 0 (0) 0 (0) Piperacillin-tazobactam 18 (14.5) 14 (12.2) Klebsiella pneumoniae N =30 N =27 Meropenem 1 (3.3) 2 (7.4) Piperacillin-tazobactam 15 (50) 12 (44.4) Abbreviations: EUCAST, European Committee on Antimicrobial Susceptibility Testing; m-mitt, microbiologic modified intent-to-treat; M-V, meropenemvaborbactam; P-T, piperacillin-tazobactam. a For P-T, the EUCAST breakpoint for resistance is a minimum inhibitory concentration of >16 µg/ml and for meropenem the breakpoint for resistance is a minimum inhibitory concentration of >8 ug/ml. b Percentage is calculated using N as the denominator, where N is the number of isolates tested for the relevant antimicrobial. Only pathogens with a frequency of at least 10 patients total are included. Only data from urinary isolates are included. If the same pathogen was isolated from the same source (urine or blood), only the result for the isolate with the highest minimum inhibitory concentration was included.
7 etable 4. Overview of Adverse Events (MITT Population) AE M-V (N=272) n (%) P-T (N=273) n (%) All treatment-emergent AEs 106 (39.0) 97 (35.5) Study drug-related AEs 41 (15.1) 35 (12.8) Life-threatening AEs 3 (1.1) 0 (0.0) All serious AEs 11 (4.0) 12 (4.4) Deaths 2 (0.7) 2 (0.7) Discontinuation of study drug due to treatment-emergent AE 7 (2.6) 14 (5.1) Discontinuation from study due to treatment-emergent AE 3 (1.1) 3 (1.1) Any severe AE 7 (2.6) 13 (4.8) ALT increased 0 (0.0) 1 (0.4) Anemia 1 (0.4) 2 (0.7) Aspiration pneumonia 0 (0.0) 1 (0.4) AST increased 1 (0.4) 1 (0.4) Azotemia 1 (0.4) 0 (0.0) Bile duct stone 1 (0.4) 0 (0.0) Blood creatine phosphokinase increased 0 (0.0) 1 (0.4) Blood creatinine increased 0 (0.0) 1 (0.4) Cerebrovascular accident 0 (0.0) 1 (0.4) Colon cancer 1 (0.4) 1 (0.4) Convulsion 0 (0.0) 1 (0.4) Dyspnea 0 (0.0) 1 (0.4) Fibrin D dimer increased 0 (0.0) 1 (0.4) Hypoglycemia 1 (0.4) 0 (0.0) Infusion-related reaction 1 (0.4) 0 (0.0) Oliguria 1 (0.4) 0 (0.0) Ureteric obstruction 1 (0.4) 0 (0.0) UTI 0 (0.0) 1 (0.4) Frequency data are for numbers of participants experiencing an event, not for numbers of adverse events. Abbreviations: AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; M-V, meropenem-vaborbactam; MITT, modified intent-to-treat; P-T, piperacillin-tazobactam.
8 ereferences 1. Meronem I.V. 500 mg. SmPC. Luton, UK; AstraZeneca UK Ltd Accessed December 6, Piperacillin/Tazobactam 4g/0.5g Powder for Solution for Infusion. SmPC. Wrexham, UK. Wockhardt UK Limited Accessed December 6, 2017.
Summary of Results for Laypersons
What was the Study Called? Summary of Results for Laypersons A Randomized, Double-blind, Parallel-group, Placebo- and Active-controlled, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability
Kenneth W. Mahaffey, MD and Keith AA Fox, MB ChB
Once-daily oral direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation Kenneth W. Mahaffey, MD and Keith AA Fox, MB ChB on behalf
National level ICD 9-3 digit Nuts II european shortlist Croatia 1999/2000 From WHO ICD-10, 4 digit. 1999/2000 From WHO ICD-10, 4 digit
Gleb Denissov Reference Period Transmission to Eurostat Data Albania 1999/2000 From WHO ICD-9, 3 digit Bulgaria 1999/2000 National level from WHO Nuts II level by e-mail National level ICD 9-3 digit Nuts
Healthcare-associated infections acquired in intensive care units
SURVEILLANCE REPORT Annual Epidemiological Report for 2015 Healthcare-associated infections acquired in intensive care units Key facts In 2015, 11 788 (8.3%) of patients staying in an intensive care unit
GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 October 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 October 2006 CUBICIN 350 mg (daptomycin), powder for perfusion solution Box of 1 bottle (CIP code: 567 219-3) CUBICIN
Supplementary Online Content
Supplementary Online Content Toyoda N, Chikwe J, Itagaki S, Gelijns AC, Adams DH, Egorova N. Trends in infective endocarditis in California and New York State, 1998-2013. JAMA. doi:10.1001/jama.2017.4287
MICHIGAN MEDICINE GUIDELINES FOR TREATMENT OF URINARY TRACT INFECTIONS IN ADULTS
When to Order a Urine Culture: Asymptomatic bacteriuria is often treated unnecessarily, and accounts for a substantial burden of unnecessary antimicrobial use. National guidelines recommend against testing
Summary of Results for Laypersons
What was the Study Called? Summary of Results for Laypersons A Phase IIIb/IV Randomized, Controlled, Open-Label, Parallel Group Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration
PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
Supplementary Online Content
Supplementary Online Content Dodick DW, Silberstein SD, Bigal ME, et al. Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial. JAMA. doi:10.1001/jama.2018.4853
Supplementary Online Content
Supplementary Online Content Powles T, O Donnell PH, Massard C, et al. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 openlabel
Plazomicin Versus Meropenem for the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis: Results of the EPIC Study
Plazomicin Versus Meropenem for the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis: Results of the EPIC Study Daniel J. Cloutier 1, Loren G. Miller 2, Allison S. Komirenko 1,
Summary of Results for Laypersons
What was the Study Called? Summary of Results for Laypersons A Multicenter, Three Arm, Randomized, Open Label Clinical Study to Compare Renal Function in Liver Transplant Recipients Receiving an Immunosuppressive
STABILITY Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY. Harvey D White on behalf of The STABILITY Investigators
STABILITY Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY Harvey D White on behalf of The STABILITY Investigators Lipoprotein- associated Phospholipase A 2 (Lp-PLA 2 ) activity:
ANTIBIOTIC USE DURING ENDOUROLOGIC SURGERY
ANTIBIOTIC USE DURING ENDOUROLOGIC SURGERY Comprehensive Kidney Stone Center at Duke University Medical Center Durham, North Carolina Glenn M. Preminger LEADING EDGE UROLOGY 49th Annual Duke Urologic Assembly
WCPT COUNTRY PROFILE December 2017 HUNGARY
WCPT COUNTRY PROFILE December 2017 HUNGARY HUNGARY NUMBERS WCPT Members Practising physical therapists 727 Total number of physical therapist members in your member organisation 4,000 Total number of practising
PARALLELISM AND THE LEGITIMACY GAP 1. Appendix A. Country Information
PARALLELISM AND THE LEGITIMACY GAP 1 Appendix A Country Information PARALLELISM AND THE LEGITIMACY GAP 2 Table A.1 Sample size by country 2006 2008 2010 Austria 2405 2255 0 Belgium 1798 1760 1704 Bulgaria
Smokefree Policies in Europe: Are we there yet?
Smokefree Policies in Europe: Are we there yet? 14 April 2015, 9:00 10:30am Rue de l Industrie 24, 1040 Brussels Permanent Partners: Temporary Partners: The research for the SFP Smokefree Map was partially
WCPT COUNTRY PROFILE December 2017 SWEDEN
WCPT COUNTRY PROFILE December 2017 SWEDEN SWEDEN NUMBERS WCPT Members Practising physical therapists 11,043 Total number of physical therapist members in your member organisation 17,906 Total number of
PACKAGE LEAFLET: INFORMATION FOR THE USER Meronem IV 500 mg and 1 g Powder for solution for injection or infusion meropenem
PACKAGE LEAFLET: INFORMATION FOR THE USER Meronem IV 500 mg and 1 g Powder for solution for injection or infusion meropenem Read all of this leaflet carefully before you start using this medicine because
WCPT COUNTRY PROFILE December 2017 SERBIA
WCPT COUNTRY PROFILE December 2017 SERBIA SERBIA NUMBERS WCPT Members Practising physical therapists 622 Total number of physical therapist members in your member organisation 3,323 Total number of practising
A Snapshot of Colistin Use in South-East Europe and Particularly in Greece
A Snapshot of Colistin Use in South-East Europe and Particularly in Greece Helen Giamarellou 02.05.2013 When Greek Physicians Prescribe Colistin? It is mainly prescribed in the ICU for VAP, bacteremia
PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI)
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: Secondary Outcome/Efficacy Variable(s): Statistical Methods:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
Comparision of Antibiotic Susceptibility Testing As Per CLSI and Eucast Guidelines for Gram Negative Bacilli
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 15, Issue 7 Ver. X (July. 2016), PP 01-05 www.iosrjournals.org Comparision of Antibiotic Susceptibility
UTI IN ELDERLY. Zeinab Naderpour
UTI IN ELDERLY Zeinab Naderpour Urinary tract infection (UTI) is the most frequent bacterial infection in elderly populations. While urinary infection in the elderly person is usually asymptomatic, symptomatic
Design and Analysis of a Cancer Prevention Trial: Plans and Results. Matthew Somerville 09 November 2009
Design and Analysis of a Cancer Prevention Trial: Plans and Results Matthew Somerville 09 November 2009 Overview Objective: Review the planned analyses for a large prostate cancer prevention study and
Overview of drug-induced deaths in Europe - What does the data tell us?
Overview of drug-induced deaths in Europe - What does the data tell us? João Matias, Isabelle Giraudon, Julián Vicente EMCDDA expert group on the key-indicator Drug-related deaths and mortality among drug
Summary of Results for Laypersons
What was the Study Called? Summary of Results for Laypersons A Multicenter, Four Arm, Randomized, Open Label Clinical Study Investigating Optimized Dosing in a Prograf -/Advagraf -Based Immunosuppressive
Annual Surveillance Summary: Pseudomonas aeruginosa Infections in the Military Health System (MHS), 2017
i Annual Surveillance Summary: Pseudomonas aeruginosa Infections in the Military Health System (MHS), 2017 Jessica R. Spencer and Uzo Chukwuma Approved for public release. Distribution is unlimited. The
Supplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Sprung CL, Annane D, Keh D, et al. Hydrocortisone therapy for
ClinialTrials.gov Identifier: sanofi-aventis. Sponsor/company: 07/November/2008
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov
Giving the Proper Dose: How Can The Clinical and Laboratory Standards Institute(CLSI)Help?
Giving the Proper Dose: How Can The Clinical and Laboratory Standards Institute(CLSI)Help? Pranita D. Tamma, M.D., M.H.S. Director, Pediatric Antimicrobial Stewardship Johns Hopkins University School of
Supplementary Online Content
Supplementary Online Content Dharmarajan K, Wang Y, Lin Z, et al. Association of changing hospital readmission rates with mortality rates after hospital discharge. JAMA. doi:10.1001/jama.2017.8444 etable
Webposting Clinical Trial Results Synopsis
Study Summary This summary information is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This summary information is not intended to replace
SYNOPSIS. Clinical Study Report IM Double-blind Period
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Abatacept () Name of Active Ingredient: Abatacept () Individual Study Table Referring to the Dossier SYNOPSIS (For National Authority
Supplementary Online Content
Supplementary Online Content Han B, Li K, Wang Q, et al. Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non small cell lung cancer: the ALTER 0303
Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin Marc S. Sabatine, MD, MPH on behalf of the PEGASUS-TIMI 54 Executive
Summary of Results for Laypersons
What was the Study Called? Summary of Results for Laypersons A Phase III, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of BAL8557 Versus a Caspofungin Followed by Voriconazole Regimen
Guillain-Barré Syndrome
Guillain-Barré Syndrome A Laboratory Perspective Laura Dunn Biomedical Scientist (Trainee Healthcare Scientist) Diagnosis of GBS GBS is generally diagnosed on clinical grounds Basic laboratory studies
DOSING GUIDE. Indications. Important Safety Information. Enable the immune system. RECOGNIZE. RESPOND.
DOSING GUIDE For patients with unresectable Stage III NSCLC following concurrent CRT For patients with locally advanced or metastatic UC previously treated with platinum-based therapy Enable the immune
The Identification of Food Safety Priorities using the Delphi Technique
The Identification of Food Safety Priorities using the Delphi Technique Gene Rowe & Fergus Bolger, GRE 58th Advisory Forum Meeting, Luxembourg, 8-9 December 2015 EU RISK ASSESSMENT AGENDA (RAA) where priorities
Diagnostic approach and microorganism resistance pattern in UTI Yeva Rosana, Anis Karuniawati, Yulia Rosa, Budiman Bela
Diagnostic approach and microorganism resistance pattern in UTI Yeva Rosana, Anis Karuniawati, Yulia Rosa, Budiman Bela Microbiology Department Medical Faculty, University of Indonesia Urinary Tract Infection
Disclosure. Financial disclosure: National Advisory Board & Research Grant from Boehringer-Ingelheim
Randomised Dabigatran Etexilate Dose Finding Study In Patients With Acute Coronary Syndromes Post Index Event With Additional Risk Factors For Cardiovascular Complications Also Receiving Aspirin and Clopidogrel
27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Vienna, Austria, April 22-25, 2017
Is Associated With Improved Survival and Safety Compared With in the Treatment of Serious Infections Due to Carbapenem-resistant Enterobacteriaceae: Results of the CARE Study Lynn E. Connolly 1, Adrian
Nilotinib AEs (adverse events) in CML population:
Nilotinib AEs (adverse events) in CML population: The percentages below were taken from a randomized trial of nilotinib 300mg BID in newly diagnosed Ph+ CML patients (N=279) taken from the Tasigna 2017
Supplementary Online Content
Supplementary Online Content Irish AB, Viecelli AK, Hawley CM, et al; for the Omega-3 Fatty Acids (Fish Oils) and Aspirin in Vascular Access Outcomes in Renal Disease (FAVOURED) Study Collaborative Group.
Where we stand in EFORT
Where we stand in EFORT Engaging with the new EU regulatory landscape for medical devices. Challenges & opportunities Brussel, Belgium April 6, 2018 Per Kjaersgaard-Andersen Associate Professor Section
Table 6.1 Summary information for colorectal cancer in Ireland,
6 Colorectal cancer 6.1 Summary Colorectal cancer is the second most common cancer in Ireland (excluding non-melanoma skin cancer). It accounts for 12% of all malignant neoplasia in females and 15% in
After acute coronary syndromes patients continue to have recurrent ischemic events despite revascularization and dual antiplatelet therapy
Randomised Dabigatran Etexilate Dose Finding Study In Patients With Acute Coronary Syndromes Post Index Event With Additional Risk Factors For Cardiovascular Complications Also Receiving Aspirin and Clopidogrel
PDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Fri, 01 Feb 2019 06:46:32 GMT) CTRI Number Last Modified On 02/06/2015 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study
Plazomicin for complicated urinary tract infection
October 2016 Horizon Scanning Research & Intelligence Centre Plazomicin for complicated urinary tract infection NIHR HSRIC ID: 9787 Lay summary Serious infections caused by Gram-negative bacteria are becoming
Infectious Disease Testing. UriSelect 4 Medium. Direct Identification Visibly Reliable
Infectious Disease Testing Urielect 4 Medium Direct Identification Visibly Reliable Urielect 4 Non selective chromogenic medium for the isolation, differentiation and enumeration of urinary tract infections
Treatment Options for Urinary Tract Infections Caused by Extended-Spectrum Β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae
Treatment Options for Urinary Tract Infections Caused by Extended-Spectrum Β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae medicine.missouri.edu/jahm/treatment-options-urinary-tract-infections-caused-extended-spectrum-β-lactamase-producingescherichia-coli-klebsiella-pneumoniae/
Summary of the risk management plan (RMP) for Zerbaxa (ceftolozane / tazobactam)
EMA/513109/2015 Summary of the risk management plan (RMP) for Zerbaxa (ceftolozane / tazobactam) This is a summary of the risk management plan (RMP) for Zerbaxa, which details the measures to be taken
PDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Fri, 09 Nov 2018 00:53:13 GMT) CTRI Number Last Modified On 30/07/2014 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study
Saudi Arabia February Pr Michel KOMAJDA. Université Pierre et Marie Curie Hospital Pitié Salpétrière
Prevention of Cardiovascular events with Ivabradine: The SHIFT Study Saudi Arabia February 2011 Pr Michel KOMAJDA Université Pierre et Marie Curie Hospital Pitié Salpétrière Paris FRANCE Declaration Of
Clinical pharmacokinetics of meropenem after the first and tenth intramuscular administration
Journal of Antimicrobial Chemotherapy (1996) 37, 775-781 Clinical pharmacokinetics of meropenem after the first and tenth intramuscular administration A. Novelli', T. Mazzei', E. Meli*, S. Conti', S. Fallani'
NICE Guidance. NICE Guidance Complicated urinary tract infections: ceftolozane/tazobactam. Full Evidence Summary
This National Institute for Health and Care Excellence (NICE) guidance is the current, unaltered NICE guidance at time of publication. BJUI publishes selected NICE guidance relevant to urologists to extend
The Global Summit of Women 2009 Santiago, Chile May 14-16
The Global Summit of Women 2009 Santiago, Chile May 14-16 Presentation on Combating Violence Against Women By Susan Arnot Heaney, Global Director, Corporate Responsibility, Avon Products, Inc. (USA) Public
Presented at the annual meeting of the American Society of Microbiology, June 1-5, 2017, New Orleans, LA, USA
Is Associated With Improved Survival and Safety Compared to Colistin in Serious Carbapenemresistant Enterobacteriaceae (CRE) Infections: Results of the CARE Study Lynn E. Connolly 1, Adrian M. Jubb 1,
Supplementary Online Content
Supplementary Online Content Schmidt B, Whyte RK, Asztalos EV, et al; for the Canadian Oxygen Trial (COT) Group. Effects of targeting higher vs lower arterial oxygen saturations on death or disability
Outpatient treatment in women with acute pyelonephritis after visiting emergency department
LETTER TO THE EDITOR Korean J Intern Med 2017;32:369-373 Outpatient treatment in women with acute pyelonephritis after visiting emergency department Hee Kyoung Choi 1,*, Jin-Won Chung 2, Won Sup Oh 3,
VABOMERE (meropenem and vaborbactam) for injection, for intravenous use Initial U.S. Approval: 2017
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use VABOMERE safely and effectively. See full prescribing information for VABOMERE. VABOMERE (meropenem
Supplementary Online Content
Supplementary Online Content Inohara T, Manandhar P, Kosinski A, et al. Association of renin-angiotensin inhibitor treatment with mortality and heart failure readmission in patients with transcatheter
Inequalities in health: challenges and opportunities in Europe Dr Zsuzsanna Jakab WHO Regional Director for Europe
Inequalities in health: challenges and opportunities in Europe Dr Zsuzsanna Jakab WHO Regional Director for Europe 21st Congress of the European Association of Dental Public Health 1 October 2016 Budapest
European Status report on Alcohol and Health
European Status report on Alcohol and Health Dr Lars Moller Regional Advisor a.i. WHO Regional Office for Europe Main killers in the WHO European Region Source: Preventing chronic diseases. A vital investment.
Engagement in language assessment / Regions of Europe
Summary table: Engagement in language / Regions of This table lists the statistically significant differences in the engagement in activities by the respondents from different s of : If the word or appears
Piperacillin Tazobactam 4g/0.5g powder for solution for injection or infusion Piperacillin and tazobactam
Package leaflet : Information for the user Piperacillin Tazobactam 4g/0.5g powder for solution for injection or infusion Piperacillin and tazobactam Read all of this leaflet carefully before you start
FOURIER STUDY GREYLOCK PRESS: CTS PRODUCT SAMPLE - FOURIER YES. Did the study achieve its main objective?
FOURIER STUDY Did the study achieve its main objective? 2 15% 1 5% 9.8% YES FOURIER compared Repatha with placebo in patients who were taking a statin and had hardening or narrowing of the arteries and
Supplementary Online Content
Supplementary Online Content Dhabangi A, Ainomugisha B, Cserti-Gazdewich C, et al. Effect of transfusion of red blood cells with longer vs shorter storage duration on elevated blood lactate levels in children
Pressure Injury Complications: Diagnostic Dilemmas
Pressure Injury Complications: Diagnostic Dilemmas Aimée D. Garcia, MD, CWS, FACCWS Associate Professor, Department of Medicine, Geriatrics Section Baylor College of Medicine Medical Director, Wound Clinic
Mesporin TM. Ceftriaxone sodium. Rapid onset, sustained action, for a broad spectrum of infections
Ceftriaxone sodium Rapid onset, sustained action, for a broad spectrum of infections 1, 2, 3 Antibiotic with a broad spectrum of activity Broad spectrum of activity against gram-positive* and gram-negative
Cross Border Genetic Testing for Rare Diseases
Cross Border Genetic Testing for Rare Diseases EUCERD Joint Action WP8 Helena Kääriäinen National Institute for Health an Welfare, Helsinki, Finland Starting point Possibilities and demand for genetic
MARKET NEWS for pig meat
MARKET NEWS for pig meat Market analysis 26 November 2018 Week 48 MARKET SITUATION Europe: Trading in legs is at slightly increasing or unchanged prices this week. Trading in other cuts is at unchanged
Urinary tract infections in children with CAKUT and introduction of the PREDICT trial Giovanni Montini, Bologna, Italy.
Urinary tract infections in children with CAKUT and introduction of the PREDICT trial Giovanni Montini, Bologna, Italy giovanni.montini@aosp.bo.it Causes of CKD (n=1197) Heredithary nephropathies 15.4%
Supplementary Online Content
Supplementary Online Content Khera R, Dharmarajan K, Wang Y, et al. Association of the hospital readmissions reduction program with mortality during and after hospitalization for acute myocardial infarction,
Urinary Tract Infections: From Simple to Complex. Adriane N Irwin, MS, PharmD, BCACP Clinical Assistant Professor Ambulatory Care October 25, 2014
Urinary Tract Infections: From Simple to Complex Adriane N Irwin, MS, PharmD, BCACP Clinical Assistant Professor Ambulatory Care October 25, 2014 Learning Objectives Develop empiric antimicrobial treatment
Scott Williams, MD Pediatric Nephrology OLOL Children s Hospital September 29, Controversies in Urinary Tract Infections
Scott Williams, MD Pediatric Nephrology OLOL Children s Hospital September 29, 2013 Controversies in Urinary Tract Infections Disclaimer I have no affiliations with any pharmaceutical or equipment company
Supplementary Online Content
Supplementary Online Content Tangri N, Stevens LA, Griffith J, et al. A predictive model for progression of chronic kidney disease to kidney failure. JAMA. 2011;305(15):1553-1559. eequation. Applying the
Biology Report. Is there a relationship between Countries' Human Development Index (HDI) level and the incidence of tuberculosis?
Biology Report Is there a relationship between Countries' Human Development Index (HDI) level and the incidence of tuberculosis? Introduction Tuberculosis is a serious disease caused by the bacterium Mycobacterium
TRANSPARENCY COMMITTEE. Opinion. 07 January 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 07 January 2009 500 mg, powder for solution for perfusion B/10 bottles (CIP: 387 355-6) Applicant: JANSSEN-CILAG doripenem
Urinary Tract Infections in Hospitalized Patients
Urinary Tract Infections in Hospitalized Patients Puerto Rico Chapter Annual Meeting Daniel C. DeSimone, MD March 9, 2019 2017 MFMER slide-1 Disclosures for speaker: Date of presentation: 3/9/2019 No relevant
CLINICAL CHARACTERISTICS AND ANTIBIOTIC RESISTANCE PATTERN OF PATHOGENS IN PEDIATRIC URINARY TRACT INFECTION
CLINICAL CHARACTERISTICS AND ANTIBIOTIC RESISTANCE PATTERN OF PATHOGENS IN PEDIATRIC URINARY TRACT INFECTION Yupaporn Amornchaicharoensuk Faculty of Medicine, Navamindradhiraj University, Bangkok, Thailand
Current levels and recent trends in health inequalities in the EU: Updates from the EU Report
Current levels and recent trends in health inequalities in the EU: Updates from the EU Report Anne Scott London Health Observatory Expert Working Group on Social Determinants and Health Inequalities Luxembourg,
Supplementary Online Content
Supplementary Online Content Gomes T, Redelmeier DA, Juurlink DN, et al. Opiod dose and risk of road trauma in Canada: a populationbased study. JAMA Intern Med. Published online January 14, 2013. doi:10.1001/2013.jamainternmed.733.
Synopsis. Adalimumab M Clinical Study Report R&D/09/060. (For National Authority Use Only) to Part of Dossier: Name of Study Drug:
Synopsis Abbott Laboratories Name of Study Drug: Individual Study Table Referring to Part of Dossier: Volume: (For National Authority Use Only) Name of Active Ingredient: Page: Title of Study: A Multi-Center,
Men & Health Work. Difference can make a difference Steve Boorman & Ian Banks RSPH Academy 2013
Men & Health Promotion @ Work Difference can make a difference Steve Boorman & Ian Banks RSPH Academy 2013 Difference can make a Difference Mens health: State of mens health Use of services Role of the
Annual Surveillance Summary: Pseudomonas aeruginosa Infections in the Military Health System (MHS), 2016
Annual Surveillance Summary: Pseudomonas aeruginosa Infections in the Military Health System (MHS), 2016 Sarah Gierhart and Uzo Chukwuma Approved for public release. Distribution is unlimited. The views
Animal species. Member State EU/EEA. Route of administration. Strength. Applicant Name INN Pharmaceutical form. Austria 1
Annex I List of the names, pharmaceutical form, strength of the veterinary medicinal product, animal species, route of administration, applicant in the Member States 1 Member State EU/EEA Applicant Name
D7.1 Report summarising results of survey of EU countries to identify volumes and trends in relation to the import and export of stem cells
Disclaimer: The content of this Deliverable represents the views of the author only and is his/her sole responsibility; it cannot be considered to reflect the views of the European Commission and/or the
URINARY TRACT INFECTIONS 3 rd Y Med Students. Prof. Dr. Asem Shehabi Faculty of Medicine, University of Jordan
URINARY TRACT INFECTIONS 3 rd Y Med Students Prof. Dr. Asem Shehabi Faculty of Medicine, University of Jordan Urinary Tract Infections-1 Normal urine is sterile.. It contains fluids, salts, and waste products,